期刊
BIOMACROMOLECULES
卷 9, 期 11, 页码 3223-3230出版社
AMER CHEMICAL SOC
DOI: 10.1021/bm800801b
关键词
-
资金
- Australian Research Council [FF0348465]
- Australian Institute Nuclear Science Engineering [AINGRA06231]
- LMUexcellent
- Australian Research Council through the award of a Federation Fellowship
- Australian Research Council [FF0348465] Funding Source: Australian Research Council
The effector capacity of endogenous lectins on cell adhesion/growth prompts studies to turn them into pharmaceutically stable forms. Using human galectin-2 as a proof-of-principle model, we first introduced mutations at the site of one of the two Cys residues, that is, C57A, C57M, and C57S. Only the C57M variant was expressed in bacteria in soluble form in high yield. No notable aggregation of the modified homodimeric lectin occurred during 3 weeks of storage. This mutational process also facilitated the site-directed introduction of poly(ethylene glycol) into the remaining sulfhydryl group (Cys75). Product analysis revealed rather complete conjugation with one chain per subunit in the homodimer. We note that neither the secondary structure alteration nor the absence of binding ability to a glycoprotein (asialofetuin) was observed. The results thus document the feasibility of tailoring a human galectin for enhanced stability to aggregation as well as monoPEGylation, which enables further testing of biological properties including functionality as growth regulator and the rate of serum clearance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据